Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The private funding rose 38% amid growing international collaborations and CDMO demand
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
